Schonfeld Strategic Advisors LLC Mersana Therapeutics, Inc. Transaction History
Schonfeld Strategic Advisors LLC
- $13.8 Billion
- Q3 2024
A detailed history of Schonfeld Strategic Advisors LLC transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 2,223,308 shares of MRSN stock, worth $3.4 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
2,223,308
Previous 2,976,918
25.32%
Holding current value
$3.4 Million
Previous $5.98 Million
29.77%
% of portfolio
0.03%
Previous 0.04%
Shares
19 transactions
Others Institutions Holding MRSN
# of Institutions
121Shares Held
116MCall Options Held
233KPut Options Held
457K-
Eco R1 Capital, LLC San Francisco, CA19.4MShares$29.6 Million1.59% of portfolio
-
Nextech Invest Ag12.1MShares$18.5 Million3.72% of portfolio
-
Vr Adviser, LLC New York, NY11.3MShares$17.3 Million2.22% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$13.3 Million2.94% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$12.8 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $149M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...